FTC Asks To Delay In-House PBM Insulin Case

Arguing that pharmacy benefit managers accused of artificially inflating insulin prices have already "unreasonably delayed" discovery, the Federal Trade Commission is asking an in-house judge to push back an evidentiary trial...

Already a subscriber? Click here to view full article